Saturday 17 October 2026
Export TXMD’s income statement to Excel — free account
TherapeuticsMD, Inc.
TXMD Healthcare Drug Manufacturers Specialty & Generic
TherapeuticsMD, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 million, up 71.6% from fiscal 2024. In the quarter to June 2026, revenue fell 8.72%, EPS fell 80.0% and free cash flow grew 104.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.90
0.03
−1.55%
Follow TXMD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
1.11% | (2.10%) | 0.67% | (0.80%) | |
Piotroski F-Score |
7 | 6 | 7 | 6 | |
| 0.77% | (1.49%) | 0.47% | (0.57%) | ||
ROIC |
(11.94%) | (14.15%) | (12.91%) | (13.77%) | |
Return on Tangible Assets |
3.16% | (5.89%) | 1.73% | (1.95%) | |
Average Days of Receivables |
478.44 | 425.75 | 349.54 | 378.84 | |
Free Cash Flow per Share |
0.18 | 0.21 | 0.23 | 0.27 | |
Free Cash Flow |
2.10 | 2.45 | 2.70 | 3.10 | |
| Other line items | |||||
Cash ROIC |
6.06% | 7.14% | 7.63% | 8.53% | |
Accounts Receivable Turnover |
0.80 | 0.85 | 1.08 | 0.92 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
220.57% | 226.74% | 200.24% | 206.12% | |
Share Based Compensation of Revenue |
1.72% | 2.48% | 1.61% | 1.74% | |
Interest Coverage |
(388.50) | — | — | — | |
Operating CF/Net income |
6.94 | (4.31) | 15.08 | (14.27) | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.24 | 0.26 | 0.29 | 0.28 | |
Operating CF per Share |
0.18 | 0.21 | 0.23 | 0.27 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates